Novel therapeutic approaches to invasive candidiasis: considerations for the clinician

F Lamoth - Infection and Drug Resistance, 2023 - Taylor & Francis
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-
hospital morbidity and mortality. The limited number of antifungal drug classes and the …
被引用次数：21 相关文章
[PDF] unil.ch

[PDF][PDF] Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician

F Lamoth - Infection and Drug Resistance, 2023 - serval.unil.ch
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-
hospital morbidity and mortality. The limited number of antifungal drug classes and the …
[HTML] nih.gov

[HTML][HTML] Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician

F Lamoth - Infection and Drug Resistance, 2023 - ncbi.nlm.nih.gov
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-
hospital morbidity and mortality. The limited number of antifungal drug classes and the …

Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician

F Lamoth - Infection and Drug Resistance, 2023 - search.proquest.com
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-
hospital morbidity and mortality. The limited number of antifungal drug classes and the …

Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician

F Lamoth - Infection and Drug Resistance, 2023 - dovepress.com
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-
hospital morbidity and mortality. The limited number of antifungal drug classes and the …

Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician

F Lamoth - Infection and Drug Resistance, 2023 - europepmc.org
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-
hospital morbidity and mortality. The limited number of antifungal drug classes and the …

Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician

F Lamoth - Infection and drug resistance, 2023 - pubmed.ncbi.nlm.nih.gov
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-
hospital morbidity and mortality. The limited number of antifungal drug classes and the …
[PDF] core.ac.uk

[PDF][PDF] Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician

F Lamoth - Infection and Drug Resistance, 2023 - core.ac.uk
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-
hospital morbidity and mortality. The limited number of antifungal drug classes and the …

Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician.

F Lamoth - Infection and Drug Resistance, 2023 - europepmc.org
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-
hospital morbidity and mortality. The limited number of antifungal drug classes and the …
[PDF] unil.ch

[PDF][PDF] Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician

F Lamoth - Infection and Drug Resistance, 2023 - serval.unil.ch
Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-
hospital morbidity and mortality. The limited number of antifungal drug classes and the …